Bioequivalence of 200 mg Amisulpride Tablets in Healthy Chinese Volunteers under Fasting and Fed Conditions.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 32, doi. 10.1002/cpdd.1348
- By:
- Publication type:
- Article
Works matching IS 2160763X AND DT 2024 AND VI 13 AND IP 1
Results: 14
1
2
Pharmacological Parameters and Pharmacokinetic Variability Derived from Bioequivalence Trials in a Mexican Population.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 6, doi. 10.1002/cpdd.1343
- By:
- Publication type:
- Article
3
The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 37, doi. 10.1002/cpdd.1337
- By:
- Publication type:
- Article
4
Effect of the Phosphate Binder Sevelamer Carbonate on the Bioavailability of Enarodustat, an Oral Erythropoiesis Stimulating Agent.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 111, doi. 10.1002/cpdd.1336
- By:
- Publication type:
- Article
5
Bioequivalence and Pharmacokinetics Study of Two Zidovudine/Lamivudine Tablets in Chinese Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 14, doi. 10.1002/cpdd.1335
- By:
- Publication type:
- Article
6
Bioequivalence of Blonanserin Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 103, doi. 10.1002/cpdd.1331
- By:
- Publication type:
- Article
7
Effect of Paricalcitol Combined with Cinacalcet on Calcium and Phosphorus Metabolism in Patients Receiving Maintenance Hemodialysis.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 96, doi. 10.1002/cpdd.1328
- By:
- Publication type:
- Article
8
Population‐Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 21, doi. 10.1002/cpdd.1323
- By:
- Publication type:
- Article
9
A Randomized Control Study in Healthy Adult Smokers to Assess Reduced Exposure to Selected Cigarette Smoke Constituents in Switching to the Novel Heated Tobacco Product DT3.0a.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 45, doi. 10.1002/cpdd.1322
- By:
- Publication type:
- Article
10
Changes in Urinary Uric Acid Concentration after Dotinurad Administration to Patients with Hyperuricemia: A Post Hoc Analysis of Two Clinical Trials in Japan.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 87, doi. 10.1002/cpdd.1317
- By:
- Publication type:
- Article
11
Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 77, doi. 10.1002/cpdd.1315
- By:
- Publication type:
- Article
12
Pharmacokinetic Properties of an FDA‐approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 58, doi. 10.1002/cpdd.1312
- By:
- Publication type:
- Article
13
Pharmacokinetic and Bioequivalence Evaluation of Single‐Tablet and Separate‐Tablet Regimens for Ainuovirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Chinese Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 70, doi. 10.1002/cpdd.1309
- By:
- Publication type:
- Article
14
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2024, v. 13, n. 1, p. 1, doi. 10.1002/cpdd.1114
- Publication type:
- Article